Related Experiment Video
Updated: Jan 30, 2026
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy
Xavier Delavenne1, Yesim Dargaud2, Edouard Ollier1
1INSERM, UMR 1059, Dysfonction Vasculaire et de l'Hémostase, Université de Lyon, Saint Etienne, France.
Insights
A Bayesian approach accurately estimates factor VIII levels in hemophilia A patients using fewer blood samples. This personalized method optimizes prophylaxis by reducing sampling needs for better treatment.
Area of Science:
- Pharmacology
- Biochemistry
- Clinical Trials
Background:
- Factor VIII (FVIII) prophylaxis is standard for hemophilia A, but patient pharmacokinetic (PK) variability necessitates personalized dosing.
- PK-tailored prophylaxis aims to achieve desired FVIII activity (FVIII:C) levels, which can vary individually.
Purpose of the Study:
- To develop a population PK model for simoctocog alfa using pooled clinical trial data.
- To create a Bayesian estimator for individual PK parameter estimation with reduced blood sampling.
Main Methods:
- Analyzed PK data from 86 adults and 29 children/adolescents with severe hemophilia A.
- Developed population PK models using nonlinear mixed-effect models for two different FVIII assays (chromogenic and 1-stage clotting).
- Utilized a Bayesian estimator to determine time above 1% FVIII:C threshold.
Main Results:
- Two-compartment models best described PK data for both assays, showing good predictive capacity.
- A limited sampling strategy (3 and 24 hours) accurately estimated time above 1% FVIII:C threshold with minimal bias and good precision for both assay methods.
- Simulations confirmed the model's predictive power.
Conclusions:
- A Bayesian approach effectively reduces the number of blood samples needed for accurate estimation of time above 1% FVIII:C.
- This method supports personalized prophylaxis strategies in hemophilia A management.
Aims:
The use of factor VIII (FVIII) prophylaxis in haemophilia A is considered the standard of care, particularly in children. Despite adjustment of doses for body weight and/or age, a large pharmacokinetic (PK) variability between patients has been observed. PK-tailored prophylaxis may help clinicians adjust coagulation factor FVIII activity (FVIII:C) to the desired level, which may differ in individual patients. The objective was to develop a population PK model for simoctocog alfa based on pooled clinical trial data and to develop a Bayesian estimator to allow PK parameters in individual patients to be estimated using a reduced number of blood samples.
Methods:
PK data from 86 adults and 29 children/adolescents with severe haemophilia A were analysed. The FVIII data measured using 2 different assays (chromogenic and the 1-stage clotting assay) were fit to separate develop population PK models using nonlinear mixed-effect models. A Bayesian estimator was then developed to estimate the time above the threshold of 1%.
Results:
The PK data for chromogenic and the 1-stage clotting assays were both best described by a 2-compartment models. Simulations demonstrated good predictive capacity. The limited sampling strategy using blood sample at 3 and 24 hours allowed an accurate estimation of the time above the threshold of 1% FVIII:C (mean bias 0.01 and 0.11, mean precision 0.18 and 0.45 for 2 assay methods).
Conclusion:
In this study, we demonstrated that a Bayesian approach can help to reduce the number of samples required to estimate the time above the threshold of 1% FVIII:C with good accuracy.
Related Concept Videos
01:15Drug Dosing: Geriatric Patients
01:21Drug Dosing: Obese Patients
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
02:27Limiting Reactant
01:09Recombinant DNA
00:57Viral Recombination